CHRONIC AMPHETAMINE ADMINISTRATION IN SCHIZOPHRENIC

持续的缺陷症状代表了最致残的 精神分裂症的症状，可能会保留后，生产或 阳性症状用现有的精神抑制剂治疗。 那些患者 似乎从安非他明的急性给药中获益的人 要求参加为期6周的每日口服给药试验， 安非他明 迄今为止，已有两名患者完成了这项双盲安慰剂对照研究。 审判 一个似乎适度受益，另一个没有明显的 变化 正式的统计分析将等待以下方面的积累： 足够多的病人。

Persistent deficit symptoms represent the most disabling of the schizophrenic symptoms that are likely to remain after the productive or positive symptoms are treated with available neuroleptics. Those patients who appear to benefit from the acute administration of amphetamine are asked to participate in a 6 week trial of daily oral dosing with amphetamine. To date, two patients have completed this double blind placebo controlled trial. One appeared to benefit modestly, the other showed no obvious change. Formal statistical analysis will await the acculmination of adequate numbers of patients.